Expand all sections

Olaparib

Lynparza

Extended indication Prostate cancer - monotherapy for BRCA 1/2 or ATM gene-mutated metastatic castration resistant prost
Therapeutic value No judgement

Product

Active substance Olaparib
Domain Oncology and Hematology
Main indication Prostate cancer
Extended indication Prostate cancer - monotherapy for BRCA 1/2 or ATM gene-mutated metastatic castration resistant prostate cancer (mCRPC) in patients who have received a prior taxane-based chemotherapy and at least one newer hormonal agent (abiraterone or enzalutamide).
Proprietary name Lynparza
Manufacturer AstraZeneca
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Orphan drug No
Additional remarks Dit is een indicatie-uitbreiding.

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Patient volume

< 53

Market share is generally not included unless otherwise stated.
References NKR; Na et al. Eur Urol. 2017 May;71(5):740-747; Kirby et al. Int J Clin Pract. 2011 Nov;65(11):1180-92
Additional remarks NKR 2015: 4432 gevallen van prostaatkanker, stadia 3 en 4. Ongeveer 6% van prostaattumoren heeft een mutatie in BRCA of ATM. 10-20% van de prostaatkankerpatienten ontwikkeld CRCP.

Expected cost per patient per year

References Medicijnkosten.nl
Additional remarks €11,78 voor een capsule van 50mg.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.